FindTrial
Sign In

Does Eating Makhana Help Improve Bone and Muscle Health in People with or at Risk of Osteoporosis?

Effect of Makhana (Euryale ferox Salisb) Supplementation on Musculoskeletal system health in individuals with and at risk of Osteoporosis - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/093636
Enrollment
100
Registered
2025-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M810- Age-related osteoporosis without current pathological fracture

Interventions

Intervention1: Makhana Arm: Participants in the intervention group will receive 60 grams of Makhana daily for a period of 6 months, made into chapatis (wheat and Makhana in a 5:1 ratio) as a meal repl

Sponsors

Indian council of Agricultural research Central Institute of Post Harvest Engineering Technology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals aged above 50 years, of post-menopausal women, with or without a diagnosis of osteoporosis. This includes: o Individuals with a T-score less or equal to -2.5 (osteoporosis) o Individuals with a T-score between -1.0 and -2.5 (osteopenia) o Individuals with normal BMD but having a high, moderate risk after administering Short OPAQ (Osteoporosis Assessment Questionnaire).

Exclusion criteria

Exclusion criteria: Individuals who use bisphosphonates, hormone replacement therapy, daily intake of highdose vitamin D (above 2000 IU/day), corticosteroids and suffering from cancer, renal diseases, congenital musculoskeletal disorders, or unwillingness to participate.

Design outcomes

Primary

MeasureTime frame
Makhana supplementation is anticipated to improve BMD (bone mineral density), particularly at the lumbar spine, femoral neck, and whole-body composition as measured by DEXA. Improvements in BMD would indicate enhanced bone mass or slowed bone loss, which is critical in both osteoporotic and at-risk populations. Timepoint: baseline at 0 months and endline at 6 months—

Secondary

MeasureTime frame
In addition, improvements in musculoskeletal function, reductions in bone resorption markers (e.g., CTX, NTX, DPD), and increases in bone formation markers (e.g., P1NP, osteocalcin) are expected. Makhana s rich nutrient profile may also contribute to increased serum calcium and vitamin D levels, reduced PTH, and improved overall bone health Timepoint: baseline at 0 months and endline at 6 months—

Countries

India

Contacts

Public ContactDr Mahesh Kumar Mummadi

ICMR National Institute of Nutrition, Hyderabad

mahidoc@yahoo.com7893370689

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026